NEW YORK (GenomeWeb) – Danaher announced this week that its board has approved a regular quarterly dividend of $.13 per share, payable on Oct. 28 to shareholders of record on Sept. 30.
Eisai said this week that it has launched the Eisai Andover innovative Medicines (AiM) Institute, focused on developing novel therapeutic targets validated by genetics research. The institute will target three therapeutic areas: immune-dementia, immune-oncology, and auto-immune disorders. The institute will also use Eisai expertise in targeting toll-like receptors and prostaglandins with small molecules. The company said it will seek collaborations with various external scientific partners in order to advance the institute's work. Current AiM collaborations are focused on human genetics, functional genomics, assay development, structural biology, computational chemistry, library synthesis, compound screening, and translational biomarkers.
Canadian biomedical company 3D Signatures went public on the TSX Venture Exchange in Toronto this week. The company's primary technology is a proprietary software platform based on the three-dimensional analysis of a patient's individual chromosomal arrangement. The company said it expects to begin further clinical trials on the platform this fall in order to prepare it for commercialization. The firm will trade under the symbol DXD.
Textile dyes manufacturer Stony Creek Colors said this week that it has received a one-year NSF grant of $224,676 with the Donald Danforth Plant Science Center to improve plant-based indigo dye production in order to make the manufacturing of blue jeans more sustainable. The partners plan to create a high-throughput handheld assay device capable of rapidly measuring naturally occurring chemicals for indigo. The Danforth Center will also perform DNA analysis of high-yielding indigo plant varieties in order to improve the understanding of indigo plant genetics. This will enable Stony Creek to produce an improved indigo-based dye.
In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the GenomeWeb site.